Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Trivalent Inactivated Influenza Vaccine for 2010-2011
NCT01140009Phase 2Completed
- Sponsor
- University of British Columbia
- Start
- Aug 2010
- Primary completion
- Sep 2010
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of influenza A virus A/California/7/2009 X-179A (H1N1) hemagglutinin antigen (formaldehyde inactivated) in influenza (2 arms), sponsored by University of British Columbia. Primary endpoints: Safety of 2010-2011 seasonal trivalent vaccine (TIV) at 12 weeks, Immune responses to each component of TIV at 12 weeks and 1 more. Started Aug 2010; status: completed.
02
Drugs
influenza A virus A/California/7/2009 X-179A (H1N1) hemagglutinin antigen (formaldehyde inactivated)
03
Conditions
influenza
Beyond the preview
Go deeper on NCT01140009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01140009.